CJC-1295: GHRH Extended Release Mechanism Explained
GH AXIS RESEARCH
GHRH ANALOGUE
CJC-1295 VARIANT
✅ RESEARCH CHEMICAL
Research Use Only. CJC-1295 is sold strictly as a research chemical for in vitro and laboratory study. This article summarises published preclinical and clinical research literature. It does not constitute medical advice, a treatment protocol, or a recommendation for human use. Consult a qualified healthcare professional before any clinical application.
The central challenge in growth hormone research using GHRH-based compounds has always been the same: native GHRH(1-44)-NH₂ has a plasma half-life of less than 7 minutes, destroyed by ubiquitous dipeptidyl peptidase-IV (DPP-IV) cleavage. Every GHRH analogue developed before CJC-1295 faced the same pharmacokinetic ceiling — short bursts of pituitary stimulation followed by rapid clearance. CJC-1295, developed by ConjuChem Biotechnologies and described formally by Jette et al. in 2005, solved this problem with an elegant molecular engineering strategy: covalent albumin binding via a maleimido-propionyl-PEG drug affinity complex (DAC). The result is a GHRH analogue with a half-life of 6–8 days — transforming a transient peptide into a sustained GH-axis research tool.
Key Takeaways
- CJC-1295 with DAC (CAS: 863288-34-0, MW: ~3,367 Da) is a modified GHRH(1-29) analogue with a Drug Affinity Complex for covalent albumin binding
- Native GHRH half-life: <7 min (DPP-IV cleavage); CJC-1295+DAC half-life: 6–8 days (albumin conjugation)
- Mechanism: GHRH-R agonism → Gαs → adenylyl cyclase → ↑cAMP → PKA → GH gene transcription + somatotroph priming
- Jette et al. (2005) demonstrated sustained IGF-1 elevation for >14 days post single injection in healthy adults
- Does not co-elevate cortisol or prolactin — more selective GH-axis profile than GHRP-2
- Synergises with GHS-R1a agonists (GHRP-2, Ipamorelin) via dual-receptor convergent GH release
Research-grade CJC-1295 with DAC from Pure Grade Labs — with full CoA and HPLC purity data.
The Drug Affinity Complex: Engineering Extended Half-Life
The Drug Affinity Complex (DAC) is ConjuChem’s proprietary platform for extending peptide half-life by enabling covalent conjugation to endogenous serum albumin — the most abundant plasma protein (35–50 g/L in human blood; t½ ~19 days). Once a drug is conjugated to albumin, it inherits albumin’s long circulating half-life, high plasma volume of distribution, and FcRn-mediated recycling protection from lysosomal degradation.
The CJC-1295 DAC chemistry works as follows:
- A maleimido propionyl (MPA) linker is attached via PEG to a lysine residue within the modified GHRH(1-29) backbone (at Lys³⁰ in the extended sequence)
- The maleimide group is highly reactive with free thiol groups (−SH), specifically the reduced Cys³⁴ on human serum albumin
- Upon injection, the maleimide-thiol Michael addition reaction proceeds spontaneously at physiological pH, forming a stable, irreversible thioether bond between CJC-1295 and albumin in plasma
- The albumin-CJC-1295 conjugate then acts as a slow-release reservoir, with the GHRH peptide remaining biologically active while attached to albumin
The reaction half-time for in vivo albumin conjugation is approximately 30–60 minutes — meaning a fraction of the injected dose is in free, unconjugated form for the first hour, producing an initial bolus GH response, followed by sustained GHRH-R stimulation from the albumin-conjugated fraction over days.
This two-phase pharmacokinetic profile — initial bolus + sustained tail — is a distinctive feature of CJC-1295+DAC not shared by Mod GRF 1-29 (CJC-1295 without DAC), which lacks the maleimide group and acts as a conventional short-acting GHRH analogue with a half-life of approximately 30 minutes.
Engineering Context — Why Albumin? ConjuChem’s insight was that albumin conjugation was superior to PEGylation (another common half-life extension strategy) for several reasons. PEGylation increases hydrodynamic radius, reducing renal filtration, but the PEG chains are inert and can accumulate. Albumin, by contrast, undergoes active recycling via the neonatal Fc receptor (FcRn) expressed in endothelial cells — the same receptor that gives IgG antibodies their long half-life. By piggy-backing onto albumin’s FcRn recycling pathway, CJC-1295 obtains half-life protection that compounds on the upper end of albumin’s own circulating lifespan. The Cys³⁴ targeting was similarly rational: this thiol is the only free cysteine on albumin, making conjugation site-specific rather than the random multi-site modification typical of amine-reactive chemistry.
GHRH-R Signalling: Gαs / cAMP / PKA Pathway
CJC-1295 binds the GHRH receptor (GHRH-R), a class B GPCR expressed primarily on anterior pituitary somatotroph cells. Unlike GHS-R1a (the ghrelin/GHRP receptor), GHRH-R couples exclusively to Gαs — there is no significant Gαq or Gα12/13 component in normal physiological GHRH-R signalling.
The GHRH-R Gαs cascade proceeds:
- Gαs activation → adenylyl cyclase (AC) stimulation → cAMP production from ATP
- cAMP activates protein kinase A (PKA) by dissociating its regulatory subunits
- PKA phosphorylates multiple targets:
- CREB (cAMP response element binding protein) → nuclear → ↑GH gene transcription
- Voltage-gated calcium channels (L-type) → ↑Ca²⁺ entry → GH granule fusion
- Somatostatin receptor desensitisation → reduced inhibitory tone
- GH secretory granules fuse with the somatotroph plasma membrane → GH pulse into portal circulation
The critical distinction from GHS-R1a signalling is that GHRH-R activation drives primarily transcriptional GH production (via CREB-mediated GH gene upregulation) in addition to acute granule exocytosis — whereas GHRP-2 / Ipamorelin via GHS-R1a drives primarily acute exocytosis via Gαq/Ca²⁺. This is the basis for the synergistic model: CJC-1295 fills the GH secretory pool (via cAMP/CREB/transcription) while GHRP-2 or Ipamorelin empties it (via Ca²⁺/exocytosis).
Jette et al. (2005): The Defining Human Study
The landmark human pharmacology study for CJC-1295 was published by Jette L, Léger R, Thibaudeau K et al. (2005) in the Journal of Clinical Endocrinology and Metabolism (PMID: 16140635). This Phase I/II dose-escalation trial enrolled 64 healthy subjects (32 male/female, aged 21–61) in 9 cohorts receiving single SC injections of CJC-1295 at doses of 30, 60, 90, 120, or 180 µg/kg, or vehicle control.
Key findings from the Jette (2005) study:
- GH levels: Dose-dependent 2–10× increase in mean 24-hour GH concentration for 6 days post-injection
- IGF-1 levels: 1.5–3× above baseline for ≥14 days post single injection at higher doses (120–180 µg/kg)
- Pulsatile pattern preserved: Critically, GH release remained pulsatile — CJC-1295 amplified pulse amplitude without converting physiological pulsatile release to continuous release
- Cortisol and prolactin: No significant elevation at any dose — confirming GH-axis selectivity
- Half-life: Terminal half-life of 5.8–8.1 days across dose cohorts, consistent with albumin conjugation
- Tolerability: Water retention reported in some subjects; no serious adverse events across all cohorts
The preservation of pulsatile GH release is a particularly important finding. Exogenous recombinant GH (rhGH) administration produces a supraphysiological surge followed by suppression of endogenous GH pulses via negative feedback — replacing the natural pulsatile pattern with a pharmacological bolus. CJC-1295’s GHRH-R agonism, by contrast, amplifies the natural GH pulse system rather than replacing it. Pulses remained entrained to the normal ultradian rhythm; CJC-1295 increased their amplitude, not their frequency or temporal pattern.
Pure Grade Labs stocks CJC-1295 with DAC alongside the full GH secretagogue range for research use.
CJC-1295 with DAC vs Without DAC (Mod GRF 1-29): Key Differences
A significant source of confusion in the GHRH analogue research literature is the inconsistent naming convention between “CJC-1295 with DAC” and “CJC-1295 without DAC” (the latter also called Mod GRF 1-29 or Modified GRF). These are structurally different compounds with substantially different pharmacokinetics:
| Property | CJC-1295 + DAC | Mod GRF 1-29 (no DAC) |
|---|---|---|
| Albumin binding | Covalent (thioether) | None |
| Half-life | 6–8 days | ~30 minutes |
| GH release pattern | Sustained amplitude ↑ | Acute pulse |
| Injection frequency | Once weekly (research) | Multiple daily |
| GHRH-R receptor | Same (Gαs/cAMP) | Same (Gαs/cAMP) |
Researchers purchasing “CJC-1295” should clarify whether the DAC modification is present — the two compounds have fundamentally different research use cases. CJC-1295+DAC is appropriate for studies requiring sustained, days-long GH axis stimulation. Mod GRF 1-29 is appropriate for acute GH pulse research or combined dosing protocols where timing precision with GHRP co-administration is required.
Synergy with GHS-R1a Agonists: GHRP-2 and Ipamorelin
The mechanistic basis for combining CJC-1295 with GHRP-2 or Ipamorelin is one of the most clearly documented synergies in peptide research biology. It operates through strictly independent receptor systems:
- CJC-1295 occupies GHRH-R → sustained Gαs/cAMP → ongoing CREB-driven GH synthesis → keeps the somatotroph pool topped up with secretory granules
- GHRP-2 or Ipamorelin occupies GHS-R1a → acute Gαq/Ca²⁺ → triggers exocytosis of the full, primed granule reservoir
- The primed somatotroph discharges more GH than an unprimed cell — the synergy is the intersection of these two independent pathways at the granule exocytosis step
In the Jette (2005) study, CJC-1295 alone at 60 µg/kg produced a mean GH AUC of approximately 385 µg·h/L over 72 hours. Published preclinical data (Nass et al., 2008; Smith et al., 2005) show that combined CJC-1295 + GHRP-2 produces GH responses that exceed the theoretical additive sum of the two compounds by approximately 40–70% — true pharmacodynamic synergy by definition (response > sum of individual responses).
Researchers choosing between GHRP-2 and Ipamorelin as the GHS-R1a agonist component should consider the cortisol confound: GHRP-2 co-elevates cortisol and prolactin; Ipamorelin does not. For studies where the GH output itself is the primary measured variable and cortisol confounding is acceptable, GHRP-2 + CJC-1295 provides the highest raw GH stimulus. For studies requiring clean GH-axis isolation without HPA perturbation, Ipamorelin + CJC-1295 is the preferred combination.
Research Context — The IGF-1 Signal: One of the most practically significant findings from the Jette (2005) trial was not the GH elevation itself but the downstream IGF-1 response. IGF-1 (insulin-like growth factor 1), produced primarily by the liver in response to GH signalling, is the mediator of many of GH’s anabolic and tissue-repair effects. In the CJC-1295 trial, a single injection at 120 µg/kg maintained IGF-1 levels 1.5–3× above baseline for at least 14 days — the entire measurement window. This sustained IGF-1 elevation profile, without continuous GH infusion and without disrupting natural GH pulsatility, was unprecedented for a GHRH analogue and established CJC-1295+DAC as a research platform for studying IGF-1’s biological effects in a sustained, physiologically patterned context.
Somatostatin Interaction and Physiological Feedback
CJC-1295’s GHRH-R agonism does not override the physiological somatostatin braking system. Somatostatin (SRIF), released from the hypothalamus, binds SSTR2/SSTR5 on somatotrophs and suppresses GH secretion via Gαi/cAMP reduction — directly antagonising the CJC-1295 Gαs/cAMP signal. This natural regulatory competition means that CJC-1295 cannot force GH secretion during high-somatostatin phases (such as late GH pulse descent) — it must work with the physiological rhythm, amplifying pulses rather than overriding the inhibitory system.
This somatostatin sensitivity is part of why CJC-1295’s GH pulses remain entrained to the physiological rhythm despite the peptide’s 6–8 day half-life. The pulsatile GH pattern is a clock-like process governed by alternating hypothalamic GHRH and somatostatin release; CJC-1295 provides sustained GHRH-R tone but the somatostatin counterpart still controls pulse timing. The result is amplified pulses at the same physiological frequency — the ideal research paradigm for studies that need more GH without losing physiological temporal patterning.
Purity, Characterisation, and Research Sourcing
CJC-1295+DAC characterisation should include MS confirmation of MW ~3,367 Da (accounting for the PEG-maleimide linker; the exact MW varies slightly by linker length and PEG MW — confirm against CoA), RP-HPLC purity ≥98%, and absence of the unreacted (free maleimide) precursor, which would react non-specifically with plasma thiols. Researchers should specifically verify that the DAC modification is present — “CJC-1295” sourced without DAC is structurally different and pharmacokinetically incomparable.
Pure Grade Labs CJC-1295 with DAC is supplied with HPLC and MS verification included in the CoA, with batch-level QR authentication.
Research Note — The Class B GPCR Distinction: GHRH-R belongs to Class B GPCRs (also called secretin-like receptors), structurally distinct from the Class A GPCRs (rhodopsin-like) that include GHS-R1a, dopamine receptors, and most other peptide receptors. Class B GPCRs bind their ligands via a two-step mechanism: the C-terminal helix of the peptide binds a large extracellular domain (ECD) first, then the N-terminal portion inserts into the transmembrane bundle to activate the receptor. This binding geometry means that GHRH truncation — such as the GHRH(1-29) fragment used in CJC-1295 — retains full receptor activity because the 29 N-terminal residues include both the ECD-binding tail and the TM-activating N-terminus, while the C-terminal residues 30–44 of native GHRH are structurally dispensable for receptor activation. This pharmacophore insight is what made GHRH(1-29) the template for all synthetic GHRH analogues, including CJC-1295.
Frequently Asked Questions
What does the DAC in CJC-1295+DAC stand for?
Drug Affinity Complex — ConjuChem’s proprietary half-life extension technology. A maleimido-propionyl-PEG linker is attached to a lysine residue on the GHRH analogue; upon injection, the maleimide group covalently bonds to Cys³⁴ on serum albumin via thiol-maleimide Michael addition. The resulting albumin-peptide conjugate has a half-life of 6–8 days, inheriting albumin’s long circulating lifespan.
How does CJC-1295 work at the receptor level?
CJC-1295 binds GHRH-R, a Class B GPCR on anterior pituitary somatotrophs. GHRH-R couples exclusively to Gαs, activating adenylyl cyclase → ↑cAMP → PKA activation. PKA phosphorylates CREB (driving GH gene transcription) and L-type calcium channels (driving granule exocytosis). This produces both an acute GH pulse and sustained GH synthesis — the pool-filling component of the GHRH/GHRP synergistic model.
What did the Jette (2005) human study find?
In 64 healthy subjects, a single SC injection of CJC-1295 produced 2–10× increases in mean 24-hour GH for 6 days and 1.5–3× IGF-1 elevation for at least 14 days. GH pulsatility was preserved (amplified pulses at normal frequency), cortisol and prolactin were unaffected, and terminal half-life was 5.8–8.1 days — confirming successful albumin conjugation and clean GH-axis selectivity.
What is the difference between CJC-1295 with DAC and Mod GRF 1-29?
Mod GRF 1-29 is CJC-1295 without the DAC albumin-binding modification. It binds the same GHRH-R but has a half-life of ~30 minutes, producing acute GH pulses rather than sustained elevation. CJC-1295+DAC produces days-long sustained GH amplitude increase from a single injection. They are different compounds for different research designs.
Why doesn’t CJC-1295 co-elevate cortisol or prolactin like GHRP-2?
CJC-1295 acts exclusively via GHRH-R, which is expressed predominantly on pituitary somatotrophs. It does not bind GHS-R1a (the ghrelin receptor) — and it is GHS-R1a expression in the hypothalamus and adrenal cortex that drives GHRP-2’s cortisol and prolactin co-elevation. CJC-1295’s GHRH-R specificity provides clean GH-axis stimulation without HPA axis activation.
Summary
CJC-1295 with DAC solves the fundamental pharmacokinetic limitation of native GHRH through a precisely engineered albumin-conjugation chemistry. By covalently binding serum albumin within 30–60 minutes of injection, CJC-1295 transforms the GHRH(1-29) backbone from a 7-minute, DPP-IV-destroyed fragment into a 6–8 day sustained GHRH-R agonist. The Gαs/cAMP/PKA/CREB pathway it activates produces both acute GH granule exocytosis and ongoing GH gene transcription — filling the somatotroph secretory pool for days.
The preservation of pulsatile GH dynamics (confirmed in Jette 2005), clean cortisol and prolactin selectivity, and the well-characterised synergy with GHS-R1a agonists make CJC-1295+DAC one of the most versatile tools in the GH-axis research toolkit. Its role as the GHRH component in GHRP combination protocols — providing sustained somatotroph priming against which acute Ca²⁺-driven GH exocytosis is maximised — remains one of the most mechanistically transparent synergies in all of peptide research.
Source CJC-1295 with DAC and the full GH secretagogue range from Pure Grade Labs.
References
- Jette L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. J Clin Endocrinol Metab. 2005;90(4):2350–2356. PMID: 16140635
- Bowers CY, Granda R, Mohan S, Kuipers J, Baumann G, Veldhuis JD. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004;89(5):2290–2300. PMID: 15126561
- Frohman LA, Downs TR, Chomczynski P. Regulation of growth hormone secretion. Front Neuroendocrinol. 1992;13(4):344–405. PMID: 1289038
- Gaylinn BD. Molecular and cell biology of the growth hormone-releasing hormone receptor. Horm Res. 1999;51(Suppl 3):1–8. PMID: 10592440
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308. PMID: 18046908
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601–611. PMID: 18981485
Disclaimer: This article is published for educational and research purposes only. CJC-1295 is sold by Pure Grade Labs strictly as a research chemical, not for human consumption or therapeutic use. The information presented summarises published preclinical and early-phase clinical literature and does not constitute medical advice, a treatment recommendation, or a prescribing guide. No claims are made regarding efficacy in humans. All research use must comply with applicable institutional and regulatory requirements.